EyeYon

Ness Ziona, Israel Founded: 2011 • Age: 15 yrs
Ophthalmic devices for corneal edema treatment are developed.
Request Access

About EyeYon

EyeYon is a company based in Ness Ziona (Israel) founded in 2011 by Nahum Ferera.. EyeYon has raised $35.1 million across 3 funding rounds from investors including GF Securities, BPC Banking Tech and Quark Venture. EyeYon offers products and services including EndoArt® and Hyper-CL™. EyeYon operates in a competitive market with competitors including CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others.

  • Headquarter Ness Ziona, Israel
  • Founders Nahum Ferera
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $35.1 M (USD)

    in 3 rounds

  • Latest Funding Round
    $25 M (USD), Series C

    Mar 15, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of EyeYon

EyeYon offers a comprehensive portfolio of products and services, including EndoArt® and Hyper-CL™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Synthetic implant to treat corneal edema and replace donor tissues.

Contact lens that enhances bioavailability of topical eye drops for conditions.

People of EyeYon
Headcount 10-50
Employee Profiles 11
Employee Profiles
People
Oriah Mioduser
Senior Product Manager
People
Anat Markovich Lemze
Director Medical Affairs & Product
People
Nicholas Helme
Lead Surgical Specialist EMEA
People
Charles Holmes
Chief Commercial Officer (CCO)

Unlock access to complete

Funding Insights of EyeYon

EyeYon has successfully raised a total of $35.1M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $25.0M
  • First Round

    (21 Apr 2015)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2021 Amount Series C - EyeYon Valuation

investors

Mar, 2017 Amount Series A - EyeYon Valuation Rimonci
Apr, 2015 Amount Series A - EyeYon Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in EyeYon

EyeYon has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GF Securities, BPC Banking Tech and Quark Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech & Life Sciences focused early stage VC firm investing in North America
Founded Year Domain Location
Venture capital firm investing in early stage healthcare startups
Founded Year Domain Location
Limited information is provided about Rimonci's activities.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by EyeYon

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - EyeYon

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Eyeyon Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of EyeYon

EyeYon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutic devices for corneal transplants are developed by CorneaGen.
domain founded_year HQ Location
Corneal collagen cross-linking technology is developed for ophthalmic applications.
domain founded_year HQ Location
Therapeutics and drug delivery systems for eye diseases are developed.
domain founded_year HQ Location
iPS cell-based technology for corneal endothelium regeneration is developed.
domain founded_year HQ Location
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Eyeyon

Frequently Asked Questions about EyeYon

When was EyeYon founded?

EyeYon was founded in 2011 and raised its 1st funding round 4 years after it was founded.

Where is EyeYon located?

EyeYon is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.

Who is the current CEO of EyeYon?

Nahum Ferera is the current CEO of EyeYon. They have also founded this company.

Is EyeYon a funded company?

EyeYon is a funded company, having raised a total of $35.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.6M, raised on Apr 21, 2015.

What does EyeYon do?

EyeYon was founded in 2011 in Ness Ziona, Israel, and operates in the ophthalmic medical device sector. Therapeutic contact lenses, such as the Hyper-CL, are developed for managing corneal pathologies. Additionally, the EndoArt implant, a polymer film attached to the posterior corneal surface, is created to address corneal edema resulting from endothelial dysfunction. Focus is placed on innovative solutions for eye-related conditions.

Who are the top competitors of EyeYon?

EyeYon's top competitors include CorneaGen, Avedro and EyeGate.

What products or services does EyeYon offer?

EyeYon offers EndoArt® and Hyper-CL™.

Who are EyeYon's investors?

EyeYon has 8 investors. Key investors include GF Securities, BPC Banking Tech, Quark Venture, Triventures, and Rimonci.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available